Document Sample
IECD Powered By Docstoc
					Cancer Disparities
DF/HCC is committed to reducing cancer disparities across all levels of research, clinical care, and institutional administration. Disparities in cancer refer to health inequities spanning the full cancer continuum, across the lifecourse. These involve social inequalities in the prevention, incidence, prevalence, detection and treatment, survival, mortality, and burden of cancer and other cancer-related health conditions and behaviors.

Initiative to Eliminate Cancer Disparities
The DF/HCC Initiative to Eliminate Cancer Disparities (IECD) is a Center-wide effort that reflects the high level of commitment of the Cancer Center to addressing cancer disparities through its research, training, and administrative activities. The goal of the initiative is to permeate this theme throughout all aspects of the organization by facilitating a focus on reduction/elimination of cancer disparities throughout all DF/HCC structure and activities. This is achieved through the facilitation of clinical trials recruitment efforts, encouraging research focused on new discovery related to understanding the causes of and solutions to cancer disparities, and the development of increased faculty and trainee diversity. Key responsibilities include: 1) forging new relationships and partnerships to support all aspects of the IECD, particularly related to community relationships, 2) managing underrepresented student training programs and helping other training programs attract minority students, and 3) supporting career development programs for DF/HCC junior investigators.

Cancer Disparities Program
The mission of the Cancer Disparities Program is to advance scientific research relevant to understanding and addressing cancer disparities, such as advancing knowledge in the scientific community and broader public about cancer disparities; increasing the number of researchers who promote the importance and implications of disparities in the context of their work; and increasing awareness of cancer disparities among researchers at DF/HCC. Specific research aims include social determinants of cancer disparities, such as social epidemiologic research, clinical research (including quality of care), and media/health communications; and solutions to cancer disparities, such as cancer screening/access to care, and risk reduction/population health interventions.

Get Involved
DF/HCC offers its members assistance with a variety of research-related activities. These include: • developing minority inclusion and community engagement language for SPORE grants • creating recruitment and outreach plans for training grants, minority recruitment plans to clinical trials, and minority faculty recruitment supplements • disparities specific funding opportunities made available through developmental funds For more information about how to get involved, contact Karen Burns White:

Continuing Umbrella of Research Experiences
The Continuing Umbrella of Research Experiences (CURE) is a central component of the IECD’s student training effort. Funded through a CCSG supplement as well as non-Core Grant funds, this program has provided transforming experiences in cancer research for more than 80 high school and undergraduate students during the past 6 years. For more information about becoming a mentor, call 617-632-3028.

Cancer Disparities (cont’d)

Contact Information
Initiative to Eliminate Cancer Disparities
Karen Burns White 617-632-3244

Learn More
For more information about the IECD or the Cancer Disparities Program, visit the DF/HCC web site:

Cancer Disparities Program
Leader: Howard Koh, MD, MPH 617-495-4000 Co-Leader: Karen Emmons, PhD 617-632-2188

About DF/HCC
Dana-Farber/Harvard Cancer Center is the largest National Cancer Institute-designated Comprehensive Cancer Center in the nation. Founded in 1998, DF/HCC is an inter-institutional research enterprise that unites all of the cancer research efforts of the Harvard-affiliated community. The primary goal of the Cancer Center is to encourage and promote collaborative interactions and translational research that will lead to new approaches to cancer prevention, diagnosis, and treatment.